CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...